TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04340479

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound lung imaging as part of FAST+ evaluation
Description: FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~1. Anterior midclavicular right and left (apical, medial, basal)~2. Posterior paraspinal right and left\* (apical, medial, basal)~   \*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~3. Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound lung imaging as part of FAST+ evaluation
Description: FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~1. Anterior midclavicular right and left (apical, medial, basal)~2. Posterior paraspinal right and left\* (apical, medial, basal)~   \*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~3. Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings.
Study: NCT01837394

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block of the SN and ONP
Description: 7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
Study: NCT03975335

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carrier Guidance
Description: Carrier opportunities and counselling
Study: NCT04359862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
Study: NCT04461613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revised IPAQ followed by an original one.
Description: Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
Study: NCT02793934

Intervention type: OTHER
Intervention: ICF reader
Study: NCT03704844

Intervention type: OTHER
Intervention: non applicable
Description: non applicable
Study: NCT04280133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video Tool
Description: The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
Study: NCT04239144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral sympathectomy
Description: Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
Study: NCT00957190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide 20 mg and Timolol 5 mg
Description: Twice daily in the affected eye(s)
Study: NCT02220530

Intervention type: DRUG
Intervention: Conscious sedation with iv midazolam and fentanyl.
Description: Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
Study: NCT01983046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Three different mixture of acetate, butyrate and propionate and palcebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Three different mixture of acetate, butyrate and propionate and palcebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Three different mixture of acetate, butyrate and propionate and palcebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Three different mixture of acetate, butyrate and propionate and palcebo
Study: NCT02002624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSI
Study: NCT01837394

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo block
Description: 7.5 ml of isotonic saline solution 154 mmol/l injected at each site
Study: NCT02002624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional instrumentation
Study: NCT01837394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 5 mg as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: 5 mg as needed
Study: NCT01186315

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
Study: NCT01837394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg i.v. as needed in the PACU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 4 mg i.v. as needed in the PACU
Study: NCT01186315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure therapy + VR/ER
Description: The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use \& CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
Study: NCT04853056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: wearing virtual reality glasses
Study: NCT01837394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg tablet as needed in the postoperative period after discharge from the PACU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg tablet as needed in the postoperative period after discharge from the PACU
Study: NCT01006577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: side-to-end anastomosis
Description: Low anterior resection for rectal cancer \< 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: colon j pouch
Description: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
Study: NCT04853056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold vibration
Description: Buzzy
Study: NCT02897076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone 24 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 12mg betamethasone +placebo
Study: NCT02392234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661/Ivacaftor
Description: Fixed dose combination tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to VX-661/ ivacaftor
Description: Fixed dose combination tablet, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to VX-661/ ivacaftor
Description: Fixed dose combination tablet, oral use
Study: NCT03976193

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BfitBwell program
Description: Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BfitBwell program
Description: Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6 bi-weekly PA Behavior Change counseling sessions
Description: Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
Study: NCT01208818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Bortezomib + Dexamethasone regimen
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~* Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib +Dexamethasone regimen
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib +Dexamethasone regimen
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib +Dexamethasone regimen
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect.
Study: NCT02392234

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to Ivacaftor
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to Ivacaftor
Description: Tablet, oral use
Study: NCT01426412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014 IV
Description: Administered IV over 30-90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014 IV
Description: Administered IV over 30-90 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Administered IV only over 30-90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014 SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014 SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Administered SC
Study: NCT01762059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-homonal Bionic Pancreas
Description: A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT00044564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bay 59-8862
Description: 75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
Study: NCT02029235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Ibuprofen
Description: Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Hydrocodone
Description: Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
Study: NCT02142751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin sodium intravenous
Description: 4g every 6 hours iv (60 min infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem intravenous
Description: 1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins

Intervention type: DRUG
Group type: OTHER
Intervention: Ceftriaxone intravenous
Description: 1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
Study: NCT00281892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fludarabine plus Darbopoetin
Description: Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine mono
Description: Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa.
Study: NCT04556981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M72/AS01E Mycobacterium tuberculosis vaccine
Description: Participants will receive an intramuscular dose of M72 (10 micrograms of recombinant fusion protein) reconstituted with AS01E (an adjuvant system), on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an intramuscular dose of saline (0.9% NaCl), on Day 1 and Day 29
Study: NCT00386945

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief counseling (Ask, Advise, Arrange)
Description: Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
Study: NCT03945578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor muscle training - PFMT
Description: Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).
Study: NCT04452201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Participation
Description: GP couples' participation together in development of communication competencies in the context of infant care will be supported by a handbook and telephone guidance structured for collaboration with the nurse/research assistant beginning at approximately 2 weeks of age. Two face-to-face sessions are expected prior to hospital discharge, followed by 5 or 6 monthly phone sessions. If the baby is inpatient at the time an intervention session is to take place, the session may be done face-to-face, if more convenient than a phone session for the parents.
Study: NCT04595305

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac resynchronization therapy by CRT-P or CRT-D implantation
Description: Clinically indicated implantation of a CRT-P or CRT-D device as per standard of care
Study: NCT03249142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM A Durvalumab/chemotherapy association
Description: NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : the tremelimumab 75 mg IV will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. Durvalumab 1125 mg IV (with one cycle of tremelimumab 75 mg IV post S3) will be pursued in maintenance treatment, up to 1 year or until disease progression, unacceptable toxicity or patient withdrawn.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B Durvalumab/Tremelimumab/chemotherapy association
Description: NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV + tremelimumab 75 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : patients will be treated according to investigator choice.
Study: NCT01472510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
Study: NCT04240613

Intervention type: DEVICE
Group type: OTHER
Intervention: TVT-O
Description: TVT-O is one of the most popular treatments for urinary incontinence (UI). Its efficacy is well established in patients with pure stress urinary incontinence (SUI). Data reporting long-term outcomes of TVT-O for the treatment of mixed urinary incontinence (MUI) or recurrent SUI is scarce. The objective of this study was to evaluate the efficacy and safety and overall patient satisfaction of TVT-O in different subgroups of UI in a long-term follow-up.